secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2025-01-07T23:59:59+00:00
Accession:  0000950170-25-002828
Event type: regulatory
Sentiment:  neutral
Materiality: 0.75
Item codes: 3.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nasdaq grants Revelation continued listing subject to reverse split and $1 price by Feb 14, 2025
--------------------------------------------------------------------------------

- Nasdaq Panel granted continued listing; must effect reverse stock split by Jan 31, 2025.
- Must maintain $1.00 bid price for 10 consecutive trading days by Feb 14, 2025.
- Regained compliance with Nasdaq equity requirement (Rule 5550(b)(1)).
- Company raised $4M from warrant exercise in December 2024.
- FDA accepted Gemini IND; Phase 1b study in chronic kidney disease expected H1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025002828/0000950170-25-002828-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017025002828/revb-20250103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-002828

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer